EVOQ Nano

EVOQ Nano has developed a proprietary, high-energy laser ablation platform that overcomes traditional manufacturing barriers to produce uniform, stable spherical metamaterials at a consistent nanoscale size (10nm ±4). This platform enables the creation of materials with unique physical properties, including demonstrated broad-spectrum antimicrobial activity, without the need for chemical capping agents or ion emission. The company's technology, published in peer-reviewed journals, represents a potential breakthrough in nanomaterial production for therapeutic and industrial applications. As a private, likely pre-revenue entity, EVOQ's key challenge is translating its promising platform into commercialized products or partnerships.

Patented high-energy laser ablation process for manufacturing uniform, stable spherical metamaterials (10nm ±4) without chemical additives or ion emission.

EVOQ competes with other companies developing novel antimicrobials (e.g., antimicrobial peptides, phage therapy) and nanomaterial-based therapeutics. Its differentiation lies in its unique, clean manufacturing process and the potential for a physical, non-leaching mechanism of action that may avoid traditional resistance pathways. However, it is a late entrant in a crowded field and must prove superior efficacy or safety.